235 related articles for article (PubMed ID: 19798624)
21. Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.
Harder BC; von Baltz S; Schlichtenbrede FC; Jonas JB
Arch Ophthalmol; 2012 Jun; 130(6):800-1. PubMed ID: 22801850
[No Abstract] [Full Text] [Related]
22. Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years.
Klufas MA; Chan RV
J Pediatr Ophthalmol Strabismus; 2015; 52(2):77-84. PubMed ID: 25798707
[TBL] [Abstract][Full Text] [Related]
23. Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (AP-ROP).
Wutthiworawong B; Thitiratsanont U; Saovaprut C; Subhangkasen I; Geyuraphun B; Ampornprut A; Phumongkutchai J; Tephusdinnaayuthaya S
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S15-21. PubMed ID: 22043749
[TBL] [Abstract][Full Text] [Related]
24. Retinopathy of prematurity: do we still have a problem?: the Charles L. Schepens lecture.
Tasman W
Arch Ophthalmol; 2011 Aug; 129(8):1083-6. PubMed ID: 21825195
[TBL] [Abstract][Full Text] [Related]
25. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.
Kychenthal A; Dorta P
Retina; 2010 Apr; 30(4 Suppl):S32-6. PubMed ID: 20224474
[TBL] [Abstract][Full Text] [Related]
26. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M
JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183
[No Abstract] [Full Text] [Related]
27. Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity.
Eldweik L; Mantagos IS
Semin Ophthalmol; 2016; 31(1-2):163-8. PubMed ID: 26959143
[TBL] [Abstract][Full Text] [Related]
28. The German ROP Registry: data from 90 infants treated for retinopathy of prematurity.
Walz JM; Bemme S; Pielen A; Aisenbrey S; Breuß H; Alex AF; Wagenfeld L; Schiedel S; Krohne TU; Stahl A;
Acta Ophthalmol; 2016 Dec; 94(8):e744-e752. PubMed ID: 27197876
[TBL] [Abstract][Full Text] [Related]
29. Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment.
Hoang QV; Kiernan DF; Chau FY; Shapiro MJ; Blair MP
Arch Ophthalmol; 2010 Aug; 128(8):1080-1. PubMed ID: 20697016
[No Abstract] [Full Text] [Related]
30. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up.
Martínez-Castellanos MA; Schwartz S; Hernández-Rojas ML; Kon-Jara VA; García-Aguirre G; Guerrero-Naranjo JL; Chan RV; Quiroz-Mercado H
Retina; 2013 Feb; 33(2):329-38. PubMed ID: 23099498
[TBL] [Abstract][Full Text] [Related]
31. Retinopathy of prematurity: the disease process, classifications, screening, treatment, and outcomes.
Harrell SN; Brandon DH
Neonatal Netw; 2007; 26(6):371-8. PubMed ID: 18069428
[TBL] [Abstract][Full Text] [Related]
32. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H
Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279
[TBL] [Abstract][Full Text] [Related]
33. [Retinopathy of prematurity - pathophysiologic mechanisms and new treatment options].
Stahl A; Aisenbrey S; Krohne TU
Klin Monbl Augenheilkd; 2012 Oct; 229(10):1024-9. PubMed ID: 22961043
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity.
Moran S; O'Keefe M; Hartnett C; Lanigan B; Murphy J; Donoghue V
Acta Ophthalmol; 2014 Sep; 92(6):e496-7. PubMed ID: 24428792
[No Abstract] [Full Text] [Related]
35. Intravitreal bevacizumab injection in advanced retinopathy of prematurity.
Choovuthayakorn J; Ubonrat K
J Med Assoc Thai; 2012 Apr; 95 Suppl 4():S70-5. PubMed ID: 22696855
[TBL] [Abstract][Full Text] [Related]
36. Acquired vasoproliferative retinal tumor: a late sequela of retinopathy of prematurity.
Chow CC; Blair MP; Shapiro MJ
Arch Ophthalmol; 2011 Sep; 129(9):1234-5. PubMed ID: 21911679
[No Abstract] [Full Text] [Related]
37. [Use of anti-VEGF (anti-vascular endothelial growth factor) in Retinopathy of Prematurity (ROP)].
González Viejo I; Ferrer Novella C; Pueyo Royo V
Arch Soc Esp Oftalmol; 2011 Jul; 86(7):207-8. PubMed ID: 21798405
[No Abstract] [Full Text] [Related]
38. Retinopathy of Prematurity: Therapeutic Strategies Based on Pathophysiology.
Cayabyab R; Ramanathan R
Neonatology; 2016; 109(4):369-76. PubMed ID: 27251645
[TBL] [Abstract][Full Text] [Related]
39. Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity.
Sato T; Shima C; Kusaka S
Am J Ophthalmol; 2011 Feb; 151(2):353-7.e1. PubMed ID: 21168819
[TBL] [Abstract][Full Text] [Related]
40. Antivascular endothelial growth factor for retinopathy of prematurity.
Mintz-Hittner HA; Best LM
Curr Opin Pediatr; 2009 Apr; 21(2):182-7. PubMed ID: 19300261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
